INTRODUCTION
============

Prostate cancer incidence varies tremendously across the world depending on ethnic, genetic, diet and environmental factors. Prostate cancer incidence is very high in the United States and Europe, where prostate-specific antigen (PSA) screening is most common. Recently, there has been a rapid increase of the incidence of prostate cancer in Korean due to an increase in PSA screenings even though the incidence in Asia is lower than in Western countries.[@B1],[@B2] The European Randomized Screening of Prostate Cancer (ERSPC)[@B3]-[@B5] and the Prostate Cancer Prevention Trial (PCPT)[@B6],[@B7] have each introduced online prostate cancer risk calculators (RC). These instruments were created based on 6288 Dutch males and 5519 North American males of several different ethnic backgrounds. These prostate cancer risk calculators are based on race, age, serum PSA level, prostate volume, family history, outcome of digital rectal exam, transrectal ultrasound (TRUS) findings, and status of prior biopsy. These two online risk calculators were also validated in several Western cohorts.[@B4],[@B8]-[@B11]

However, no research exists investigating the applicability of these tools in Asian populations considering the low overall incidence rate of prostate cancer. Therefore, we investigated the predictive ability of the two online calculators-PSA alone and PSA density-to determine whether these tools can be applied in the Korean population.

MATERIALS AND METHODS
=====================

A retrospective analysis was performed on 625 male patients who underwent systemic 12-core TRUS-guided biopsy consecutively in our institution between January 2008 and November 2010. According to limitations of each calculator, 24 men with a PSA level \<0.5 ng/mL or \>50 ng/mL (limitation of ERSPC-RC), 1 man with prostate volume \<10 mL or \>150 mL (limitation of ERSPC-RC) and 84 men with age \<55 years old (limitation of PCPT-RC) were excluded. In total, 122 men were excluded. Therefore, 517 cases were ultimately used for analysis. Patients were referred for biopsy if there was suspicious malignancy, if PSA elevation was observed during follow-up and/or if PSA \>4.0 at initial screening without evidence of benign condition for PSA elevation.

Clinical factors evaluation
---------------------------

To obtain risk estimates, necessary predictor variables for the tools were gathered, including age, family history, status of prior prostate biopsy, PSA level, prostate volume, distal rectal exam (DRE) findings, TRUS findings and history of 5-alpha reductase inhibitor (5-ARI) use. PSA density (PSAD) was calculated by dividing the PSA level by the prostate volume.

Risk calculators
----------------

Variables of the PCPT-RC included race, age, PSA level, family history, abnormalities of DRE, prior status of biopsy and history of 5-ARI use. For the ERSPC-RC, the four PCPT-RC variables of PSA level, abnormalities of DRE, prior status of biopsy and history of 5-ARI use, the two additional predictors of prostate volume and TRUS findings were used. In the ERSPC-RC, PSA was doubled for patients taking a 5-ARI more than 1 year before performing risk calculations, although the use of 5-ARI is not a variable for ERSPC-RC. PSA doubling was already accounted for as a variable in the risk calculations of the PCPT-RC. And we used the ERSPC-RC 4 to calculate risks for patients undergoing initial biopsy, whereas the ERSPC-RC 5 was used for those who had a previous negative biopsy.

Statistical analysis
--------------------

Continuous variables were reported as median and range values and categorical variables were reported as their number and frequency. Chi-square tests and ANOVA were used for statistical comparison of continuous and categorical variables, respectively. Simple and multiple logistic regressions were performed to identify independent predictors of prostate cancer during biopsy. The area under the receiver operating characteristics curve (AUC) was calculated for both risk calculators, PSA and PSAD for PSA screening cohort. Differences in predictive accuracy estimates were tested for statistical significance using the Hosmer and Lemeshow test. Performance characteristics of the risk calculators were examined using calibration plots, where the x-axis represented the predicted probability and the y-axis represented the actual observed proportion of positive biopsy results.

All tests were two-sided with significance noted at 0.05. Statistical analyses were performed using the SAS statistical package (Version 9.1; SAS Institute, Cary, NC, USA).

RESULTS
=======

Prostate cancer was diagnosed in 125 patients (24.1%). The characteristics of the total study population of 517 patients are shown in [Table 1](#T1){ref-type="table"}. In the simple logistic regression analysis, family history, previous biopsy history and history of 5-ARI use were not statistically significant predictors of prostate cancer. In the multiple logistic regression analysis with a backward variable selection procedure, the significant predictors of prostate cancer were age, PV, and PSA level ([Table 2](#T2){ref-type="table"}).

A significantly higher AUC was observed for the ERSPC-RC (77.4%) compared to the PCPT-RC (64.5%) and PSA level alone (64.1%) in the total patient group (*p*\<0.01). However, there was no statistically significant difference in AUC between the ERSPC-RC (77.4%) and PSAD (76.1%) (*p*=0.54) ([Fig. 1A](#F1){ref-type="fig"}). When we compared the AUCs in the over 4.0 ng/mL PSA group, the ROC analyses showed an AUC for the ERSPC-RC of 77.7%, for the PCPT-RC of 64.3%, for PSA level alone of 63.6% and for PSAD of 76.9%. In the PSAD over 0.15 group, the ROC analyses showed respective AUC values of 75.3%, 61.2%, 56%, and 71.1%. Statistically significant differences were also observed between the ERSPC-RC and the PCPT-RC and PSA in the two separate groups. However, there was no statistically significant difference between the AUC values for ERSPC-RC and PSAD among these two groups ([Fig. 1B and C](#F1){ref-type="fig"}, [Table 3](#T3){ref-type="table"}).

Analyzing the calibration plots for the total patient group, both risk calculators tended to overestimate the risk of positive biopsy. However, the overestimation of the ERSPC-RC tended to less than that of the PCPT-RC. When comparing the ERSPC-RC and PSAD, the ERSPC-RC showed overall better calibration than PSAD, as shown in [Fig. 2](#F2){ref-type="fig"} (Hosmer and Lemeshow Goodness-of-Fit Test Pr\>ChiSq 0.19 for ERSPC, 0.02 for PSAD).

DISCUSSION
==========

Various efforts to develop predictive models for prostate cancer based on clinical, laboratory, ultrasonography and magnetic resonance imaging results have been given toward improving the rate of prostate cancer detection. However, many urologists commonly use PSA level alone, PSAD, PSA velocity, DRE findings or TRUS findings in the practical clinic.

Recently, two prostate cancer risk calculators for the prediction of prostate cancer were developed and validated in several cohorts.[@B4],[@B8]-[@B11] Several studies reported that these tools are more beneficial than PSA alone in the assessment and decision making for patients with a risk of prostate cancer. Several external validation reports have shown that using PCPT-RC and ERSPC-RC improve prediction compared to using PSA alone when determining when to perform a biopsy.[@B8],[@B9] Also, some studies have found ERSPC-RC to have more prediction power and more accurately estimate the risk for prostate cancer compared to the PCPT-RC.[@B4],[@B10],[@B11] However, there are no studies investigating the validity of the ERSPC-RC or the PCPT-RC in Asians. There are also no studies comparing the two calculators in Asian populations.

External validations of the objectivity of nomograms are important to confirm the performance of these tests because they are often useful only for the cohorts from which they were developed. In addition, there is a limited efficacy of nomograms when externally validated with other study cohorts. Furthermore, it is possible to develop a novel nomogram for Korean to predict prostate cancer with our database rather than investigating the validity of Western based nomograms. However, there are over 100 different published prediction nomograms for prostate cancer through July 2007 in the field of urology.[@B12] Therefore, the present analysis aimed to address these concerns. Another main concern is that these two popular prostate cancer risk calculators were released on the internet to the general public and can be confusing to patients who are worried about their own risk of prostate cancer. Therefore, external validation is needed to determine the objective performance of these online prostate cancer risk calculators.

In the present study, the ERSPC-RC is a better prediction tool of prostate cancer after biopsy than the PCPT-RC, although the ERSPC-RC uses only five variables in comparison to the seven variables of the PCPT-RC. When we compared the four predictive tools we found similar AUCs for ROC curves between the ERSPC-RC and PSAD and between PCPT-RC and PSA level. This result is similar in two separate groups (PSA over 4.0 ng/mL group and PSAD over 0.15 group).

Several studies showed that the performance of the PCPT-RC for predicting prostate cancer is higher than that of PSA level alone.[@B8],[@B13],[@B14] However, we found that there was no statistically significant difference observed in the present study. The PCPT-RC demonstrates that ethnicity and family history are the one of variables for predicting prostate cancer; however, the inclusion of \'other races\' including Asian as a variable option reduces its ability to predict prostate cancer based on self-regulation. Another reason that we failed to observe a significant difference in the performance of PCPT-RC is that patients who had a family history of prostate cancer are not as prevalent in Asians compared with Western cohorts. Many urologists in Korea find it difficult to uncover a patient\'s actual family history in Korean prostate cancer patients.[@B15] The percentage of patients with a family history of prostate cancer was 2.3% (12 of 517 patients) in our total cohort. Just ten years ago, information about prostate cancer did not receive much attention in developing Asian countries, including Korea. For these reasons, the PCPT-RC has structural limitations to predict prostate cancer for Asians although it was proven to be effective in several Western cohorts.

The ERSPC-RC performed better than the other predictors according to the AUC values, although not statistically different from PSAD. For ERSPC-RC, prostate volume and TRUS abnormality must be gathered precisely by performing TRUS, but this tool does not include race or a family history of cancer, in contrast to the PCPT-RC. In Korea, urologists typically perform TRUS for patients who visited the out-patient clinic as the initial evaluation tool to measure the prostate size. DRE information and TRUS abnormality is also gathered when TRUS is performed. Therefore, the ERSPC-RC appears to have more predictable power than the PCPT-RC according to the differences of the accuracy in the variables that were gathered for each tool. ERSPC-RC showed a slightly improved performance for predicting prostate cancer based on the effect of the other added information from TRUS and DRE in comparison with PSAD, which is calculated using PSA levels and prostate volume.

Nevertheless, compared to another Western studies, the AUC-based value of performance of the ERSPC-RC is lower in our Korean cohort.[@B4],[@B9]-[@B11],[@B16] This result is reflected in the significant differences in clinical characteristics of prostate cancer such as PSA level, rate of DRE abnormalities and prostate volume in different races.[@B17],[@B18] Therefore, the racial differences affect the accuracy of this nomogram. For the ERSPC-RC to achieve better performance than PSAD and to demonstrate similar performance to that in other Western studies, more men who are diagnosed with prostate cancer after prostate biopsy or who have the significant prostate cancer can potentially have more proportion of the abnormalities on DRE or TRUS than the patients who do not have prostate cancer. However, there is as lower proportion of the abnormalities on DRE or TRUS in Asians, which plays an important role in ERSPC-RC in comparison with Western counterparts.[@B17],[@B18]

In the evaluation of calibration plots, both risk calculators tended to overestimate the risk of prostate cancer in the present study. Compared with the two risk calculators, the overestimation of the ERSPC-RC was lower than that of the PCPT-RC. The overestimation might be explained due to the differences between the cohorts as the source of the development for each risk calculators, even though the calibration plot was affected by multiple factors including several variables. Interestingly, the analysis of consistency of accuracy between the ERSPC-RC and PSAD showed that the ERSPC-RC more consistently predicts prostate cancer than PSAD. Despite this result, we cannot assume that the ERSPC-RC is more useful than PSAD because there was no significant difference between the AUC values between the ERSPC-RC and PSAD.

There are some limitations in this study. It is unknown how many urologists use nomograms to predict prostate cancer before prostate biopsy pathology is reported or to decide when to perform a biopsy. We can gain sufficient information using the PSA, DRE and TRUS including prostate volume clinically. PSA and prostate volume have been proven to be excellent tools to decide when to perform procedure biopsy.[@B19]-[@B21] Nevertheless, we analyzed the present study using Western based prostate cancer risk calculators to externally validate them using Korean cohorts. This study was limited by the small sample size, which could explain why the Western based prostate cancer risk calculators did not show a significant performance when compared to using PSAD for Koreans.

In conclusion, the ERSPC-RC improved predictive ability of prostate cancer when compared with PCPT-RC and PSA in this Korean cohort. However, the difference in performance between the ERSPC-RC and PSAD is not significant. The Western based prostate cancer risk calculators, including ERSPC-RC, may be sufficient for public use as an online prostate cancer risk calculator. However, we find no specific advantage to applying them for clinical practice in Korea.
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###### 

Baseline Characteristics of Patients
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PSA, prostate-specific antigen; PV, prostate volume; DRE, distal rectal examination; PSAD, PSA density; PCPT-RC, Prostate Cancer Prevention Trial Risk Calculator; ERSPC-RC, European Randomized Study for Screening in Prostate Cancer Risk Calculator.

###### 

Simple and Multiple Logistic Regression Analysis for Biopsy Outcome

![](ymj-54-665-i002)

OR, odds ratio; CI, confidence interval; 5-ARI, 5 α-reductase inhibitor; TRUS, transrectal ultrasonography; DRE, distal rectal examination; PV, prostate volume; PSA, prostate-specific antigen.
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Comparison of Areas Under Receiving Operating Characteristics Curves for the ERSPC-RC, the PCPT-RC, PSA, and PSAD
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AUC, area under the curve; CI, confidence interval; ERSPC-RC, European Randomized Screening of Prostate Cancer Risk Calculator; PCPT-RC, Prostate Cancer Prevention Trial Risk Calculator; PSA, prostate-specific antigen; PSAD, PSA density.
